The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health ...

Uterine cancer cases and deaths are projected to increase in Black women and White women in the United States.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Breast cancer survivors have a lower risk of Alzheimer's disease than cancer-free control individuals, data suggest.

Under the “One Big Beautiful Bill Act," 10.9 million Americans would lose health insurance by 2034, according to estimates by the Congressional Budget Office.

These findings suggest a need to investigate whether age-specific trends are due to guidelines that suggest reduced screening for older age groups,” the researchers wrote.

President Donald Trump’s “One Big Beautiful Bill” cuts federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion over a decade, according to the nonpartisan Congressional ...

The FDA has removed the REMS program requirement for currently approved BCMA- and CD19-directed autologous CAR T-cell therapies.

Cuts that would target states could translate into fewer health services, medical professionals, and even hospitals, especially in rural communities.